BioPharma Dive January 25, 2022
Ned Pagliarulo

Dive Brief:

  • Johnson & Johnson is hunting for biotech and medical device companies to buy, top executives said Tuesday, as they prepare to split the drugmaker in two and spin off its consumer health division by next year.
  • Their focus, however, will be on acquisitions that are smaller or mid-sized, rather than larger, potentially more disruptive deals that executives said are harder to make work financially and operationally.
  • “We are constantly looking at M&A as a key source of growth for our business,” said Joaquin Duato, J&J’s new CEO after longtime chief executive Alex Gorsky stepped down from the role this month. “We’ll continue with our focus on tuck-in acquisitions but not excluding, if the situation is granted, to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article